Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

LA Godoy, J Chen, W Ma, J Lally, KA Toomey… - Biomarker …, 2023‏ - Springer
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

PE Postmus, KM Kerr, M Oudkerk, S Senan… - Annals of …, 2017‏ - annalsofoncology.org
Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …

Risk stratification in lung resection

M Salati, A Brunelli - Current surgery reports, 2016‏ - Springer
Abstract Purpose of Review Surgery is considered the best treatment option for patients with
early stage lung cancer. Nevertheless, lung resection may cause a variable functional …

Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer: American College of …

A Brunelli, AW Kim, KI Berger, DJ Addrizzo-Harris - Chest, 2013‏ - Elsevier
Background This section of the guidelines is intended to provide an evidence-based
approach to the preoperative physiologic assessment of a patient being considered for …

[HTML][HTML] 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

J Vansteenkiste, L Crino, C Dooms, JY Douillard… - Annals of …, 2014‏ - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

[HTML][HTML] Definition and assessment of high risk in patients considered for lobectomy for stage I non–small cell lung cancer: The American Association for Thoracic …

A Pennathur, A Brunelli, GJ Criner, H Keshavarz… - The Journal of Thoracic …, 2021‏ - Elsevier
Objective Lobectomy is a standard treatment for stage I non–small cell lung cancer, but a
significant proportion of patients are considered at high risk for complications, including …

[HTML][HTML] Anesthetic considerations for lung resection: preoperative assessment, intraoperative challenges and postoperative analgesia

D Lederman, J Easwar, J Feldman… - Annals of translational …, 2019‏ - ncbi.nlm.nih.gov
This article is intended to provide a general overview of the anesthetic management for lung
resection surgery including the preoperative evaluation of the patient, factors influencing the …

[HTML][HTML] Diagnosis and management of peripheral lung nodule

T Khan, Y Usman, T Abdo, F Chaudry… - Annals of …, 2019‏ - ncbi.nlm.nih.gov
A solitary pulmonary nodule (SPN) is a well-defined radiographic opacity up to 3 cm in
diameter that is surrounded by unaltered aerated lung. Frequently, it is an incidental finding …

The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all …

LM Vernooij, WA van Klei, KGM Moons… - Cochrane Database …, 2021‏ - cochranelibrary.com
Background The Revised Cardiac Risk Index (RCRI) is a widely acknowledged prognostic
model to estimate preoperatively the probability of develo** in‐hospital major adverse …

Prognostic value of 6-min walk test to predict postoperative cardiopulmonary complications in patients with non-small cell lung cancer

H Lee, HK Kim, D Kang, S Kong, JK Lee, G Lee, S Shin… - Chest, 2020‏ - Elsevier
Background The risk stratification value of the 6-min walk test (6MWT) to decide the
feasibility of surgical resection is not well elucidated in patients with non-small cell lung …